Ocular Therapeutix, Inc., a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration, diabetic retinopathy, and other diseases and conditions of the eye, announced that it will participate at two investor conferences in May:
